ID;Term;Depth;IC Nuno;IC zhou;IC sanchez;IC resnik;IC RZ;IC Rnormalized;IC Nuno org;Annotated Genes Set number
GO:0016525;negative regulation of angiogenesis;8.0;0.811012628672052;0.780506314336026;9.32314260294094;151.1079732353669;5.192106149009898;0.005057447875840929;0.6405245499179943;[FASLG, PRL, HHEX, CCR2, HGS, CX3CR1, PLK2, TIE1, CXCL10, TEK]
GO:0014068;positive regulation of phosphatidylinositol 3-kinase signaling;8.0;1.0;0.875;9.628524252492122;238.41769229280743;5.602686357784832;0.007979625599047746;0.6615216408886768;[CCL5, PDGFC, PDGFRB, F2R, PTK2, GH1, KIT, CD28, TEK]
GO:0035684;helper T cell extravasation;9.0;0.8933024483968273;0.8428918493787028;9.474373572664863;63.467001142674015;9.777073627680469;0.002124183411652594;0.896240625180289;[CCL2]
GO:2000483;negative regulation of interleukin-8 secretion;10.0;1.0;0.9152410118609203;9.628524252492122;753.9724324201893;7.8311634786251565;0.02523477878196853;0.8157270763441555;[ANXA1]
GO:0036499;PERK-mediated unfolded protein response;6.0;1.0;0.8231203125901445;9.628524252492122;80.02054155744251;7.292166977892469;0.0026782155121157316;0.6960420709600095;[CCL2, ATF3]
GO:0034112;positive regulation of homotypic cell-cell adhesion;6.0;0.8653626801206646;0.7558016526504768;9.427853557029971;52.782758271627834;7.9853141584524145;0.001766591417952991;0.7314896500084853;[CCL5, PDPN, TNFSF11]
GO:0051928;positive regulation of calcium ion transport;8.0;0.7043150770688792;0.7271575385344395;8.848365694942547;69.31158403183679;5.085725745451326;0.002319796341169766;0.6350842511328143;[CXCL9, LGALS3, PDGFRB, TRPC1, F2R, ATP1B1, XCL1, KCNE3, CD19, CCL5, CCL4, CCL2, CCR1, WFS1, CAV1, CXCL10, P2RX5, CD4, CXCL11, F2RL3]
GO:0034351;negative regulation of glial cell apoptotic process;8.0;0.9326813400603323;0.8413406700301662;9.5544162803384;104.32654737607098;7.697632086000634;0.003491715652880169;0.7686572628545723;[CCL2, DLL1]
GO:1901741;positive regulation of myoblast fusion;9.0;1.0;0.896240625180289;9.628524252492122;353.2013099653272;6.8867018697843045;0.011821329983997786;0.7484268790654467;[CXCL9, TNFSF14, FLT3LG]
GO:0045765;regulation of angiogenesis;6.0;0.7043150770688792;0.675277851124584;8.817594036275793;44.93985318205118;4.1639455212923995;0.0015040964427611868;0.5360646801923071;[PLXND1, CXCL13, CDH5, C3AR1, PROK2, GHSR, HGS, ADAM12, AGTR1, C5AR1, JUP, PLK2, TNFSF12, CXCL10, NRP1, FASLG, PRL, HHEX, CCR2, ANXA1, ANXA3, GAB1, CEACAM1, CHI3L1, ENG, CX3CR1, PTGS2, DLL1, GPNMB, CXCR2, TIE1, LRG1, TEK]
GO:1901740;negative regulation of myoblast fusion;9.0;1.0;0.896240625180289;9.628524252492122;353.26084893783826;8.67846133901236;0.011823322699826135;0.8400575416471059;[CXCL10]
GO:0042531;positive regulation of tyrosine phosphorylation of STAT protein;11.0;1.0;0.9324289523296623;9.628524252492122;1230.2749798860389;5.618190544320798;0.04117619640118775;0.7197434780388068;[IFNA2, GHR, CCL5, IL6R, LYN, GH1, KIT]
GO:0090050;positive regulation of cell migration involved in sprouting angiogenesis;11.0;1.0;0.9324289523296623;9.628524252492122;645.2358217485536;6.7325511899570465;0.021595462279385098;0.7767319332797141;[NRP1, ANXA1, PLK2, PTGS2]
GO:1900138;negative regulation of phospholipase A2 activity;8.0;1.0;0.875;9.628524252492122;83.36451349999537;8.67846133901236;0.002790135243653613;0.8188169164668168;[ANXA1]
GO:0045920;negative regulation of exocytosis;8.0;0.7140352122741334;0.7320176061370667;9.004369943419128;172.2069348332117;6.375876246018314;0.005763611132688151;0.701062607729944;[ANXA1, GNAI2, CEACAM1, FCGR2B, IL13RA2, CCR2]
GO:0007259;JAK-STAT cascade;7.0;0.9326813400603323;0.8172600352873667;9.510741216835738;26.42836680105094;6.221725566191056;8.845336528452411E-4;0.6690987000520388;[LYN, PRL, GHR, GH1, CCL2, CCR2]
GO:2000518;negative regulation of T-helper 1 cell activation;11.0;1.0;0.9324289523296623;9.628524252492122;343.04631122454646;9.777073627680469;0.011481451315049374;0.9324289523296623;[XCL1]
GO:0050796;regulation of insulin secretion;9.0;0.8259837884571596;0.8092325194088689;9.533214072687796;205.48125160941495;4.61801832846594;0.006877272570246766;0.6324062972578516;[KCNG2, GHSR, BLK, CNR1, CCL5]
GO:0010819;regulation of T cell chemotaxis;10.0;0.9326813400603323;0.8815816818910864;9.574457031221845;194.94068539511468;7.292166977892469;0.006524489304947852;0.7881627702307852;[CXCL10, TNFSF14, CCL5, XCL1, CXCL13, CCR2]
GO:0010818;T cell chemotaxis;8.0;0.8436909121759173;0.7968454560879586;9.446202695698167;127.60944988880927;7.292166977892469;0.004270973446729658;0.747921758369865;[CXCL10, CXCL9, CXCL11, DEFA1, CXCL16, CCR2]
GO:0048247;lymphocyte chemotaxis;7.0;0.7671156992804218;0.7344772148974115;9.303101852057495;94.37808318069546;5.926926025970411;0.003158749509297446;0.6540226378555745;[CXCL9, CCL20, DEFA1, CXCL13, CXCL16, CXCL10, CXCL11, CCL7, CCL5, CCL4, CCL2, XCL1, CCR2]
GO:0045892;negative regulation of transcription, DNA-templated;10.0;0.556709148698489;0.6935955862101648;8.520155788878647;1581.2569993850602;2.683669001811703;0.05292324873051003;0.5524839694169422;[EHMT2, SLA2, MYB, MEF2C, ATF3, ELANE, PKIG, EZH2, PAWR, PAX5, AES, MMP12, FLNA, NR1H2, LGR4, GMNN, DACH1, TLE4, FOXO1, NACC2, WFS1, BCL6, CIITA, FASLG, HHEX, RFC1, XCL1, RBBP8, E2F7, KLF8, KLF5, ZNF608, EDNRB, RUNX2, PCBP3, EGR1, BCL11A, IFNA2, PTPRK, XPO1, CD36, ARID4A, BASP1, CCNE1, TGFB1, CBX4, CAV1, HMGA1, NR4A2, MXD1, HMGB2, FBP1, MEIS2]
GO:0048246;macrophage chemotaxis;8.0;1.0;0.875;9.628524252492122;95.91852822164125;7.212124270218933;0.0032103068185073717;0.7438283705770736;[CX3CR1, LGALS3, EDNRB, NUP85, CCL5, CCL2, AZU1]
GO:0048245;eosinophil chemotaxis;9.0;1.0;0.896240625180289;9.628524252492122;130.2972973825895;6.7325511899570465;0.004360933283440787;0.740543606130341;[LGALS3, CCL7, CCL5, CCL4, CCL2]
GO:0002518;lymphocyte chemotaxis across high endothelial venule;8.0;0.9326813400603323;0.8413406700301662;9.55953138100517;95.76437754181396;9.777073627680469;0.003205147533980157;0.875;[CXCL13]
GO:0010536;positive regulation of activation of Janus kinase activity;11.0;1.0;0.9324289523296623;9.628524252492122;2488.7782735422925;7.8311634786251565;0.08329716906043155;0.8329150168128974;[GH1, CCL5, IL6R]
GO:2000353;positive regulation of endothelial cell apoptotic process;9.0;1.0;0.896240625180289;9.628524252492122;129.82178199018807;6.943860283624253;0.00434501821119318;0.7513499630073597;[FASLG, CCL2]
GO:2000110;negative regulation of macrophage apoptotic process;9.0;1.0;0.896240625180289;9.628524252492122;256.26138950429646;7.9853141584524145;0.008576838086431384;0.8046099625986299;[GHSR, CCL5, CCR5]
GO:2000513;positive regulation of granzyme A production;7.0;1.0;0.8509193652572005;9.628524252492122;76.06278562175245;9.777073627680469;0.002545752982697279;0.8509193652572005;[XCL1]
GO:0032689;negative regulation of interferon-gamma production;6.0;0.8933024483968273;0.7697715367885581;9.427853557029971;65.25422870398782;6.343086423195323;0.002184000309729388;0.647506047256038;[CD274, LILRB1, INHBA, PDCD1LG2, XCL1, TLR4, HAVCR2]
GO:0050679;positive regulation of epithelial cell proliferation;6.0;0.7192862368539868;0.682763431017138;8.647694999480395;65.06748660449396;4.584116776790259;0.002177750219716307;0.5575522577384293;[NRP1, NRP2, HMGB2, CDH3, AKT1, GHSR, ARG1, MMP12, AGTR1, C5AR1, TGFA, IQGAP3, CCL5, TGFB1, EGR3, TNFSF12, NR4A1, LRG1, TEK]
GO:0070723;response to cholesterol;6.0;0.9326813400603323;0.7894609826203107;9.523163736834295;80.91680144162417;6.686031174322154;0.002708212523857764;0.665044257777226;[ABCA1, OSBPL7, TGFB1, INHBA, CCR5]
GO:0030260;entry into host cell;6.0;0.7369933605727446;0.6916169928765168;8.68406264365127;26.98811751292015;5.212725436212633;9.032680054285688E-4;0.5896993338145817;[SCARB2, TFRC, CDH1, ANPEP, CLEC5A, ITGB6, CCR5, CR2, CR1, CXADR, GYPA, CXCR4, NCAM1, GPR15, CD4]
GO:0050729;positive regulation of inflammatory response;7.0;0.657518819034173;0.679678774774287;8.587070377663961;125.85203775116636;4.973052582947213;0.0042121544440509905;0.6052415056197167;[TNFSF11, FFAR2, CCR2, IL17RB, BTK, AGTR1, TLR10, TLR7, TLR4, S100A8, TLR2, SUCNR1, TNFRSF11A, PTGS2, PLA2G7, CNR1, CCL4, NLRP12, CD6, CD28]
GO:0061844;antimicrobial humoral immune response mediated by antimicrobial peptide;6.0;1.0;0.8231203125901445;9.628524252492122;44.28377145688295;5.682729065458369;0.0014821379778550245;0.6137353412716126;[CXCL6, CXCL9, HIST1H2BK, CXCL1, CXCL13, CXCL2, CXCL5, CAMP, DEFA4, RNASE6, RNASE3, DEFA1, CXCL10, CXCL11, LTF]
GO:0071361;cellular response to ethanol;6.0;1.0;0.8231203125901445;9.628524252492122;330.81194821622347;7.138016298065211;0.011071978195372667;0.6881587980249038;[CCL7]
GO:2000406;positive regulation of T cell migration;10.0;0.7980440201809971;0.8142630219514189;9.461470167828956;351.7821234142529;6.518977089658987;0.011773831087318304;0.7486218033895181;[TNFSF14, CCL20, CXCL13, PYCARD, CXCL10, CCL5, XCL1, CCR2]
GO:1901509;regulation of endothelial tube morphogenesis;6.0;0.8933024483968273;0.7697715367885581;9.405380701177911;45.7200117395938;8.390779266560578;0.0015302076475850206;0.7522251544931926;[CXCL10]
GO:0002920;regulation of humoral immune response;5.0;0.5916390046238794;0.58606051417286;8.201407896851975;25.624977988756285;4.925043363760852;8.576449523007288E-4;0.5421079585215889;[C5AR1, CXCL13, IGHG1, IGKC, CD19, IGLV1-44, C3AR1, CR2, CR1, FCER2, FCGR2B, IGKV3-20]
GO:0051770;positive regulation of nitric-oxide synthase biosynthetic process;7.0;1.0;0.8509193652572005;9.628524252492122;147.28763043943843;7.069023426578259;0.0049295844405465;0.7124295520356204;[CCL20, LRRK2, FCER2, CCL2, TLR4, TLR2]
GO:0045662;negative regulation of myoblast differentiation;6.0;0.9326813400603323;0.7894609826203107;9.541512875502493;114.62387697121986;6.518977089658987;0.0038363580074348307;0.6565011041187423;[TGFB1, DLL1, CXCL10]
GO:0002407;dendritic cell chemotaxis;7.0;0.8653626801206646;0.7836007053175329;9.485423408851448;93.27947089202779;6.8867018697843045;0.0031219799446826077;0.7031056191423581;[CCR1, CXCR1, CCL5, CXCR2, CXCR4, CCR6, CCR5, CCR2]
GO:0030816;positive regulation of cAMP metabolic process;10.0;0.8259837884571596;0.8282329060895002;9.526741558182179;1396.5025295312637;6.139487467954083;0.04673968289273128;0.7292146864874571;[CXCL10, LHCGR, CXCL9, CXCL11, RAMP1, TSHR]
GO:0050726;positive regulation of interleukin-1 alpha biosynthetic process;9.0;1.0;0.896240625180289;9.628524252492122;1101.0209221136138;9.777073627680469;0.03685017940864447;0.896240625180289;[CCL20]
GO:0010820;positive regulation of T cell chemotaxis;11.0;1.0;0.9324289523296623;9.628524252492122;1408.745447987039;7.379178354882098;0.04714944235553481;0.8098004765652196;[TNFSF14, CCL5, XCL1, CXCL13, CCR2]
GO:0050727;regulation of inflammatory response;6.0;0.5272636092234699;0.5867521172018795;7.400047131651798;31.586589572713706;3.8007227183825356;0.00105717472691369;0.517489449159909;[EDNRB, C3AR1, TNFSF11, IL1R1, IL1R2, BTK, AGTR1, PLA2G7, CD19, ELANE, LYN, BST1, CD28, FFAR2, CCR2, ANXA1, IL17RB, TLR10, TLR7, TLR4, TLR2, PTGS2, NT5E, IGKC, NLRP12, ZYX, CDH5, IGHG1, GHSR, S100A8, SUCNR1, CALCRL, C5AR1, TNFRSF11A, IGLV1-44, NLRP3, SELE, BCL6, IGKV3-20, TNFAIP6, CR2, CR1, TNFRSF1B, XCL1, CNR1, CCL5, CCL4, CD6, TEK, FCGR2B]
GO:0031584;activation of phospholipase D activity;8.0;1.0;0.875;9.628524252492122;67.57805180902054;7.9853141584524145;0.0022617765777498177;0.7833693374183408;[CCL5]
GO:0018149;peptide cross-linking;7.0;0.6007507099811141;0.6512947202477576;8.117066748418225;151.15475272427284;5.69953618377475;0.005059013543235805;0.6423939107509793;[ANXA1, F13A1]
GO:0071407;cellular response to organic cyclic compound;5.0;0.5310727365277519;0.5557773801247963;7.0299582842316;63.0333181336412;3.907776714546695;0.0021096684316296343;0.4900848947730398;[AQP9, AKT1, MEF2C, KCNQ1, ABCB4, ABCA1, EGR1, JUP, NOX4, EZH2, GABRB1, ANXA1, ARG1, PTAFR, PTGS2, GNAI1, P2RY13, SLC8A1, CDH1, BLM, FOXO1, OSBPL7, TGFB1, CAV1, INHBA, ALPL, SLC26A3, LRRK2, DNM2, COLEC12, P2RY6, CCL5, CCL2, RAD51, KLF5]
GO:0045948;positive regulation of translational initiation;9.0;0.7586651285174919;0.775573189439035;9.39368466141472;1253.3709905068713;6.409777797693995;0.04194919909160693;0.7240369598395108;[CCL5]
GO:1905563;negative regulation of vascular endothelial cell proliferation;8.0;1.0;0.875;9.628524252492122;108.34661668819432;8.390779266560578;0.0036262637549294456;0.8041048419030481;[MEF2C, CCL2]
GO:0043922;negative regulation by host of viral transcription;11.0;1.0;0.9324289523296623;9.628524252492122;272.3838172918008;7.292166977892469;0.009116441235236167;0.8053507106995271;[CCL5, CCL4]
GO:0035782;mature natural killer cell chemotaxis;9.0;1.0;0.896240625180289;9.628524252492122;95.76437754181396;9.777073627680469;0.003205147533980157;0.896240625180289;[XCL1]
GO:0031340;positive regulation of vesicle fusion;7.0;0.8259837884571596;0.7639112594857803;9.392135474427892;149.60751655096118;7.697632086000634;0.005007228940937215;0.7445766281117727;[ANXA1]
GO:0008284;positive regulation of cell proliferation;5.0;0.5587538620495764;0.5696179428857084;7.270369308343265;43.45254999490143;2.9881018846882994;0.0014543177435732513;0.44305268120482816;[PID1, TFRC, MYB, AKT1, PROK2, MEF2C, CLDN7, AGTR1, ATF3, HHLA2, IQGAP3, PDGFC, ELANE, LYN, CDC6, CDKN1A, HLA-DPA1, HAVCR2, ANXA1, ARG1, FCRL3, MMP12, HBEGF, PTAFR, PTGS2, EPCAM, FLNA, IL12RB2, LRG1, HLA-DPB1, CHRM1, CTGF, FGF5, PYCARD, CDH3, F2R, MSH6, CD274, BLM, CALCRL, TNFRSF11A, CORO1A, NACC2, CXCL10, BCL6, FASLG, XCL1, CX3CR1, CCL5, KLF5, TCL1A, EDNRB, SKP2, ICOSLG, FLT3LG, RUNX2, BTC, TGFA, EGR1, EGR3, TNFSF12, PTK2, BST1, CD28, CD24, CD320, NRP1, NRP2, PRL, CD3E, CCR2, RHOG, PDCD1LG2, AVPR1A, CEACAM6, KIT, GNAI2, CXCR2, LILRB2, SIRPG, IL6R, PDGFRB, GHSR, CCNE1, PRTN3, C5AR1, LTBP3, TGFB1, NR4A1, HMGB2, LAMC2, CXCL5, GLP2R, MMP9, TGFBR3, LTF, DLL1, S1PR3, EGF, MEIS2, TSHR, CD4, CD6, TEK]
GO:0045663;positive regulation of myoblast differentiation;6.0;0.9326813400603323;0.7894609826203107;9.541512875502493;114.26328322821418;6.7325511899570465;0.00382428925936973;0.6674232935401965;[MEF2C, CXCL9, TNFSF14, FLT3LG]
GO:0046632;alpha-beta T cell differentiation;7.0;0.7140352122741334;0.7079369713942671;9.04870575723918;90.58502354652471;6.166155715036245;0.0030317992168737967;0.6662568552797195;[BLM, ANXA1, BCL11B, BMX, GPR18, IL18R1]
GO:0045944;positive regulation of transcription by RNA polymerase II;11.0;0.5461734764479651;0.7055156905536448;8.363590748376499;1463.8556817380634;2.718315475161805;0.048993932283191266;0.5714437321440341;[EHF, PID1, SPIB, MYB, AKT1, MEF2C, ATF3, JAG1, JUP, FZD5, PAX5, MMP12, ENG, EPCAM, NR1H2, ATAD2, GTF2H1, PLXND1, FOXO1, CXCL10, MAFF, CIITA, HHEX, CEBPE, E2F5, E2F7, KLF5, POU2AF1, CCNH, TNFSF11, SLC11A1, EBF1, FLT3LG, RUNX2, BEX1, EGR1, EGR2, EGR3, BCL11B, CD28, PRL, TLR4, TLR2, LILRB1, ARID4A, ADRB2, NLRP3, TGFB1, HMGA1, INHBA, NR4A2, NR4A1, TCF4, HMGB2, SLC40A1, ARHGEF10L, CKAP2, DLL1, MEIS2, RBMX]
GO:0043524;negative regulation of neuron apoptotic process;8.0;0.7866048967936545;0.7683024483968273;9.245532000236016;179.62959498689688;4.864418741944418;0.006012040888071555;0.6237666006816429;[NRP1, CHL1, MEF2C, F2R, MSH2, LRP1, C5AR1, SLC30A10, CORO1A, CCL2, WFS1, GABRA5, NR4A2]
GO:0048661;positive regulation of smooth muscle cell proliferation;6.0;0.9326813400603323;0.7894609826203107;9.523163736834295;63.45804869205661;5.433268205826786;0.002123883781187112;0.6009779013089371;[MYB, AKT1, SKP2, IL6R, PDGFRB, MMP9, HBEGF, CALCRL, PTAFR, PTGS2, GNAI2, CCL5, ELANE]
GO:0050850;positive regulation of calcium-mediated signaling;8.0;0.7763722522362496;0.7631861261181248;9.283683766200392;239.92176968958296;6.039404009397101;0.008029965715936047;0.6838554019015759;[TREM2, CD3E, CCL4, TRAT1, P2RX5, CD4]
GO:0000165;MAPK cascade;9.0;0.7436939687323844;0.7680876095464813;9.236482164716097;231.45054935470895;4.069963362931594;0.007746441594931149;0.6043787408332628;[IL5RA, FGF5, TNFSF11, PDGFRB, MEF2C, MAP2K2, BTC, CSF2RB, IQGAP3, RASGRP4, TGFB1, PTK2, LAT, LRRK2, CCR5, SPTAN1, MAP4K1, DUSP6, KIT, HBEGF, CCL5, CCL2, NCAM1, EGF, IL2RB, TEK]
GO:0043491;protein kinase B signaling;6.0;1.0;0.8231203125901445;9.628524252492122;26.42836680105094;6.250713103064308;8.845336528452411E-4;0.6427820713687392;[TGFB1, TSC2, TMEM100, CCL5, AKT1, CCL2]
GO:0034605;cellular response to heat;5.0;0.8436909121759173;0.712086467948879;9.260799472366804;50.43140892920004;5.666199763507158;0.0016878938715389536;0.5800107312719123;[CDKN1A, PTGS2, LYN, CXCL10]
GO:0032703;negative regulation of interleukin-2 production;6.0;0.8933024483968273;0.7697715367885581;9.427853557029971;65.25422870398782;6.7325511899570465;0.002184000309729388;0.6674232935401965;[LAG3, XCL1, HAVCR2]
GO:0045672;positive regulation of osteoclast differentiation;9.0;0.9326813400603323;0.8625812952104552;9.587702257971866;840.7838216260375;6.599019797332524;0.0281402778535103;0.7337148045016781;[CCR1, TMEM64, TNFSF11]
GO:0070100;negative regulation of chemokine-mediated signaling pathway;8.0;0.9326813400603323;0.8413406700301662;9.577230958104572;306.6761070193533;8.16763571524637;0.010264173311360264;0.7926932703116032;[CCL5, PADI2]
GO:0046883;regulation of hormone secretion;7.0;0.5326392268888578;0.6172389787016295;7.769625480426438;67.7447061739125;4.2087291239193725;0.0022673543493635607;0.5661539683803571;[KCNG2, MYB, TNFSF11, GHSR, AGTR1, BLK, INHBA, FFAR2, ANXA1, RETN, CNR1, CCL5]
GO:0019064;fusion of virus membrane with host plasma membrane;7.0;0.9326813400603323;0.8172600352873667;9.541512875502493;56.73089801191601;7.8311634786251565;0.0018987321019653565;0.7514054297404357;[CD4, CXCR4, CCR5]
GO:0014839;myoblast migration involved in skeletal muscle regeneration;7.0;1.0;0.8509193652572005;9.628524252492122;22.014357120524497;9.083926447120524;7.368007211888268E-4;0.8154717862087246;[ANXA1]
GO:0019221;cytokine-mediated signaling pathway;6.0;0.6039883530135606;0.6251144890969248;7.604142487995313;26.50247477320489;3.309374901576116;8.87013979980389E-4;0.49236189895841853;[AKT1, FPR1, FLRT2, HLA-DQA1, HLA-DRB4, CDKN1A, LRRC4, HLA-DPA1, ANXA1, FCER2, HLA-DQB1, LRRC19, PTAFR, PTGS2, ALOX5, IL12RB2, CCL20, HLA-DPB1, CSF3R, F13A1, IL5RA, CXCL13, PYCARD, IGHG1, IL13RA2, IFNA14, IFNA16, IFNA10, TNFRSF11A, FOXO1, TNFRSF17, IFNA21, TNFRSF10C, TNFRSF10B, CXCL10, CXCL11, BCL6, LCN2, HLA-DRA, CIITA, ITGAM, FASLG, TNFRSF1B, XCL1, CX3CR1, CCL7, CCL5, CCL4, CCL2, FCGR1B, IL2RB, TNFSF11, ACSL1, IL1R1, IL1R2, FLT3LG, CCR10, CCR1, EGR1, TNFSF14, TNFSF12, SDC1, IFNA5, IFNA4, IFNA7, TNFRSF13B, IFNA2, IFNA8, CCR9, CCR6, CD36, CCR5, CCR2, IL17RB, CEACAM1, KIT, RHOU, CXCR5, CXCR4, CXCR6, CXCR1, CXCR2, IL18R1, IL18RAP, CCRL2, IL6R, PRTN3, CSF2RB, TGFB1, CXCL6, CXCL9, CXCL1, CXCL2, CXCL5, GHR, LRRTM4, MMP9, SAMHD1, NCAM1, CD4, LTBR]
GO:0051262;protein tetramerization;6.0;0.8933024483968273;0.7697715367885581;9.405380701177911;42.032160359171186;4.917261223318797;0.00140677858073304;0.5745892802266999;[CDA, NUP54, ACPP, FBP1, NLGN1, HM13, SAMHD1, CD79A, CCL5]
GO:2000538;positive regulation of B cell chemotaxis;11.0;1.0;0.9324289523296623;9.628524252492122;1000.5321764499969;9.083926447120524;0.03348691152528284;0.8969813732811862;[XCL1]
GO:0006816;calcium ion transport;8.0;0.6696747006330769;0.7098373503165385;8.690254613899192;35.67391733828006;4.3132418226548594;0.001193973908871026;0.5955793873968269;[DENND5B, SLC8A1, CTGF, F2R, CACNA2D3, CALCRL, PSEN2, CORO1A, CCR1, CAV1, ATP2A3, FASLG, CCR5, TRPC7, TRPC1, TMEM37, XCL1, SLC24A1, SLC24A4, CCL5, RAMP1]
GO:0010759;positive regulation of macrophage chemotaxis;10.0;1.0;0.9152410118609203;9.628524252492122;998.0472698001994;7.292166977892469;0.033403743935984914;0.7881627702307852;[CCL5, C5AR1, C3AR1]
GO:2000134;negative regulation of G1/S transition of mitotic cell cycle;9.0;0.7980440201809971;0.7952626352707877;9.394909401310617;355.88113835876356;5.244474134527214;0.011911021428637128;0.6644432763129993;[CDKN1A, PCNA, GPNMB, NACC2, CCL2, SFN, E2F7, PLK2, CNOT3, EZH2]
GO:0033634;positive regulation of cell-cell adhesion mediated by integrin;6.0;1.0;0.8231203125901445;9.628524252492122;97.9646140837123;8.390779266560578;0.003278787470953165;0.7522251544931926;[CCL5, CXCL13]
GO:2000412;positive regulation of thymocyte migration;11.0;0.9326813400603323;0.8987696223598284;9.587702257971866;410.00503100626815;9.083926447120524;0.013722499407208136;0.8969813732811862;[XCL1]
GO:0044344;cellular response to fibroblast growth factor stimulus;6.0;1.0;0.8231203125901445;9.628524252492122;97.48528473772916;6.444869117505266;0.003262744749111514;0.6527112189764278;[EGR3, NR4A1, CCL5, CCL2]
GO:0051281;positive regulation of release of sequestered calcium ion into cytosol;13.0;0.8933024483968273;0.9092061889660501;9.585964638073326;905.0686146861244;6.139487467954083;0.03029183202467376;0.7765286393941734;[CXCL9, TRPC1, F2R, CXCL10, CXCL11, CD19, XCL1, F2RL3]
GO:0001780;neutrophil homeostasis;6.0;1.0;0.8231203125901445;9.628524252492122;41.67181410794555;8.16763571524637;0.0013947181159950893;0.7408135829017477;[ANXA1, JAM3]
GO:0090280;positive regulation of calcium ion import;9.0;0.8653626801206646;0.8289219652406215;9.420884887713877;92.69484377077161;6.8867018697843045;0.0031024130010644134;0.7484268790654467;[PDGFRB, LGALS3, CCL2]
GO:0007517;muscle organ development;4.0;0.7763722522362496;0.6381861261181248;8.753055515138222;27.682183388997124;5.085725745451326;9.264977656821302E-4;0.5100842511328143;[SGCE, BASP1, MEF2C, EGR3, CXCL10, HBEGF]
GO:0002467;germinal center formation;5.0;1.0;0.7902410118609202;9.628524252492122;29.459500770284833;7.697632086000634;9.859829789520339E-4;0.6838982747154925;[MEF2C, BCL6, CXCL13]
GO:2000427;positive regulation of apoptotic cell clearance;9.0;0.9326813400603323;0.8625812952104552;9.571365838652174;227.08343208129315;7.8311634786251565;0.007600278109940302;0.7967266896635242;[CCL2]
GO:0071663;positive regulation of granzyme B production;7.0;1.0;0.8509193652572005;9.628524252492122;91.76586570378727;9.083926447120524;0.0030713209411884286;0.8154717862087246;[XCL1]
GO:0071385;cellular response to glucocorticoid stimulus;8.0;0.8436909121759173;0.7968454560879586;9.454170865347344;407.2980594846617;5.734022359845919;0.01363189950649617;0.6682381701418294;[ABCB4, FOXO1, TGFB1, ANXA1, ARG1]
GO:0030593;neutrophil chemotaxis;9.0;1.0;0.896240625180289;9.628524252492122;130.2972973825895;5.382624473008031;0.004360933283440787;0.671508291047556;[CXCL6, CXCL9, CSF3R, C5AR1, CXCL1, CXCL13, CXCL2, CXCL5, LGALS3, CXCR1, CCL7, CCL5, CXCR2, CCL4, CCL2, CXADR, CCL20, CXCL10, CXCL11, XCL1, S100A8]
GO:0035768;endothelial cell chemotaxis to fibroblast growth factor;9.0;1.0;0.896240625180289;9.628524252492122;91.92245058705075;9.777073627680469;0.003076561696314011;0.896240625180289;[CXCL13]
GO:2000545;negative regulation of endothelial cell chemotaxis to fibroblast growth factor;11.0;1.0;0.9324289523296623;9.628524252492122;1104.3280194323595;9.777073627680469;0.03696086497970853;0.9324289523296623;[CXCL13]
GO:0035924;cellular response to vascular endothelial growth factor stimulus;6.0;1.0;0.8231203125901445;9.628524252492122;62.59148538135601;6.599019797332524;0.00209488068703431;0.6605944919115335;[NR4A1, NRP1, EGR3, ANXA1, AKT1]
GO:0033625;positive regulation of integrin activation;7.0;0.9326813400603323;0.8172600352873667;9.5544162803384;140.3817219977405;8.16763571524637;0.004698449899916962;0.7686126355688037;[CXCL13]
GO:0070459;prolactin secretion;9.0;1.0;0.896240625180289;9.628524252492122;236.67564318465372;8.390779266560578;0.007921320783140251;0.8253454670833372;[ANXA1]
GO:0030073;insulin secretion;9.0;0.9326813400603323;0.8625812952104552;9.587702257971866;236.67564318465372;6.166155715036245;0.007921320783140251;0.711578115202808;[ANXA1]
GO:0061098;positive regulation of protein tyrosine kinase activity;11.0;0.8436909121759173;0.8542744084176208;9.55953138100517;2154.6219316186807;5.8650506222523235;0.07211325701743153;0.7323679139043926;[TGFA, GRM5, CCL5, STAP1, ACE, EGF, CD24]
GO:0006887;exocytosis;6.0;0.6696747006330769;0.657957662906683;8.375761283996754;37.082880499217325;3.1596706497059923;0.0012411306378830758;0.4847060165558207;[, CDA, CYFIP1, ABCA13, C3AR1, RNASE3, RNASE2, PADI2, FPR1, FPR2, ELANE, LYN, JUP, AZU1, LYZ, TCN1, SIGLEC9, PYGL, OLR1, ANXA3, ARG1, NFAM1, ANXA5, F5, SERPINB10, PTAFR, ALOX5, FLNA, GSN, LRG1, SLCO4C1, SIGLEC5, HP, F13A1, APEH, PYCARD, CLEC5A, LAMP2, CD177, OLFM4, CLEC4D, SLC27A2, S100A8, BRI3, HVCN1, LIN7A, GPR84, CORO1A, ATP8B4, DEFA4, DEFA1, LCN2, LAT, ITGAM, FCAR, FCGR3B, CR1, TNFRSF1B, PECAM1, BPI, ACPP, CCL5, FCGR2A, P2RX1, FOLR3, LGALS3, ANPEP, ACTN1, SLC11A1, ACTN4, CHIT1, SLPI, CRISPLD2, TLN1, STXBP2, MGST1, CCR1, PRG2, NBEAL2, BST1, VNN1, ORM1, CTSS, GLIPR1, CTSG, CD36, SPTAN1, CAMP, CD33, MME, RHOG, LAT2, CEACAM1, CEACAM6, KIT, TLR2, LILRA3, STX11, CXCR1, CXCR2, CD58, LHFPL2, LILRB2, LILRB3, QPCT, CD97, CHRNB4, CD93, OSCAR, DOK3, PRTN3, C5AR1, MGAM, TGFB1, SYT2, MS4A3, TNFAIP6, CRISP3, CXCL1, SIRPB1, HK3, MMP8, SYNGR3, MMP9, CHI3L1, LTF, CLEC12A, RETN, EGF, CD9, S100P, PTX3]
GO:0043547;positive regulation of GTPase activity;6.0;0.9326813400603323;0.7894609826203107;9.523163736834295;49.33745512692421;3.758480413184235;0.001651280222271285;0.5153291757075998;[RACGAP1, EZH2, DENND1B, NRP1, ARHGAP6, RHOG, RANBP1, CCL20, SIPA1, CXCL13, RGS1, F2R, TSC2, ACAP1, PRTN3, ADAP2, LRRK2, TBC1D9, ARAP3, ALDH1A1, XCL1, CCL7, CCL5, CCL4, CCL2]
GO:0002685;regulation of leukocyte migration;7.0;0.5577261244500507;0.6297824274822259;8.169909229792605;50.8327261637902;4.6122876537569555;0.0017013255982186238;0.586791970363642;[CXCL13, PYCARD, LGALS3, C3AR1, IL6R, IL1R1, PADI2, C5AR1, FPR2, PLA2G7, KLRK1, STAP1, ELANE, LYN, CCR1, TGFB1, TNFSF14, BST1, CXCL10, CXCL11, GPR18, CXCL6, CXCL9, CXCL1, CXCL2, CXCL5, CCR6, CCR2, ANXA1, XCL1, PTAFR, CCL7, CCL5, CXCR2, CCL4, CCL2, JAM3, CCL20]
GO:0030502;negative regulation of bone mineralization;7.0;0.9326813400603323;0.8172600352873667;9.55953138100517;172.15796001199809;6.943860283624253;0.005761971989496609;0.7060287030842711;[CCR1]
GO:0002676;regulation of chronic inflammatory response;7.0;0.7586651285174919;0.7302519295159464;9.0689084645567;34.07149622250282;7.57984905034425;0.0011403423162113378;0.738553198190834;[CCL5]
GO:0050870;positive regulation of T cell activation;8.0;0.6260725219892441;0.688036260994622;8.781226392104918;216.0655637178415;4.493869898942481;0.007231519971253338;0.6048167156182404;[CD83, TFRC, SIRPG, PYCARD, GRAP2, MYB, AKT1, TNFSF11, IL6R, ICOSLG, CD274, BLM, HHLA2, CORO1A, KLRK1, BTLA, NLRP3, ICOS, LYN, TGFB1, EGR3, TNFSF14, CAV1, VNN1, BCL6, CD28, CD24, CD3E, SIRPB1, CCR2, HLA-DPA1, HAVCR2, ANXA1, PDCD1LG2, XCL1, CCL5, CCL2, LILRB1, LILRB2, CD4, CD6, HLA-DPB1]
GO:2000558;positive regulation of immunoglobulin production in mucosal tissue;10.0;1.0;0.9152410118609203;9.628524252492122;466.5056489120817;9.083926447120524;0.015613524241260885;0.8797934328124444;[XCL1]
GO:0042063;gliogenesis;5.0;1.0;0.7902410118609202;9.628524252492122;21.75937296335754;7.9853141584524145;7.282666309192915E-4;0.6986103492792611;[ANXA1]
GO:0070365;hepatocyte differentiation;5.0;1.0;0.7902410118609202;9.628524252492122;24.20171999872632;7.212124270218933;8.100097882234571E-4;0.659069382437994;[HHEX, ANXA1, E2F7]
GO:0051607;defense response to virus;6.0;0.8653626801206646;0.7558016526504768;9.485423408851448;78.89111305633469;4.573066940603674;0.0026404145566033123;0.5569871686019774;[PYCARD, IFNA14, IFNA16, RNASE6, RNASE2, IFNA10, NLRP3, IFNA21, AZU1, DEFA1, CXCL10, IFNA5, IFNA4, IFNA7, CXCL9, IFNA2, IFNA8, TLR8, TLR7, UNC93B1, SAMHD1, LILRB1]
GO:2000556;positive regulation of T-helper 1 cell cytokine production;10.0;1.0;0.9152410118609203;9.628524252492122;941.8516928651488;9.083926447120524;0.03152292854870455;0.8797934328124444;[XCL1]
GO:0051209;release of sequestered calcium ion into cytosol;14.0;0.7980440201809971;0.874941375347699;9.527428135620752;522.9340415463636;5.9928839937622085;0.01750213176047399;0.7823957313958061;[F2R, FASLG, XCL1, CCR5]
GO:0019722;calcium-mediated signaling;7.0;0.7192862368539868;0.710562483684194;8.712233520617966;27.814661162170232;4.835431205071165;9.309316775279788E-4;0.598203541955087;[MCTP1, LRRK2, SLC8A1, GRM5, EDNRB, CCRL2, CCR9, TNFSF11, CCR6, CCR5, CCR2, AVPR1A, ATP1B1, LAT2, BTK, AGTR1, CX3CR1, CXCR5, CXCR4, FPR2, CXCR6, CXCR1, CXCR2, CCR10, CCR1, CCL20, AZU1, SELE, LAT]
GO:0035754;B cell chemotaxis;8.0;0.9326813400603323;0.8413406700301662;9.55953138100517;95.76437754181396;7.9853141584524145;0.003205147533980157;0.7833693374183408;[CXCL13]
GO:2000553;positive regulation of T-helper 2 cell cytokine production;10.0;1.0;0.9152410118609203;9.628524252492122;874.8811381751227;7.9853141584524145;0.029281484352815565;0.8236103492792612;[NLRP3, XCL1]
GO:0090303;positive regulation of wound healing;7.0;0.7043150770688792;0.7030769037916401;8.753055515138222;62.345319237194666;5.905872616772578;0.002086641727724376;0.6529459655301135;[PDPN, CD36, ANXA1, F2R, TLR4, HBEGF]
GO:0045859;regulation of protein kinase activity;9.0;0.5608425510848448;0.6766619007227115;8.333797084897721;159.5555227474585;3.0974744418360864;0.005340179755709658;0.5546456121830788;[, AKT1, PROK2, FPR1, IQGAP3, FLRT2, PRKAR2B, PDGFC, SFN, ELANE, LYN, ACE, FZD5, CDC6, AZU1, NOX4, PKIG, EZH2, CDKN1A, LRRC4, DUSP2, DUSP1, DUSP6, LRRC19, CDKN2C, GTF2H1, PKN1, PYCARD, MAP2K2, F2R, ADAM9, BLM, TNFRSF11A, PKMYT1, DRD4, TNFRSF10B, CXCL10, CSPG4, LAT, LRRK2, HHEX, CCL5, CCNH, TCL1A, PPP2R1A, TNFSF11, ACSL1, SLC11A1, TGFA, EGR1, PTK2, CD24, MAP4K1, CEACAM1, KIT, TLR4, CXCR4, IL6R, PDGFRB, TSC2, HGS, CCNE1, C5AR1, ADRB2, STAP1, TGFB1, CAV1, GH1, GHR, GRM5, LRRTM4, NUP62, PSRC1, CHI3L1, LTF, EGF, CD4]
GO:0007186;G-protein coupled receptor signaling pathway;5.0;0.5508212674310002;0.5656516455764204;7.20077601654407;23.17027026302992;2.605416804911955;7.75488093814194E-4;0.4234821484283897;[EDNRB, GPR171, C3AR1, AKT1, PROK2, PTGDR, TAS2R10, TAS2R13, TAAR2, TRHR, ADCY9, AGTR1, FPR1, FPR3, FPR2, CCR10, CCR1, ABCA1, GPR15, FZD5, OR2J2, AZU1, NMBR, MARCO, PNOC, GPR18, GPR19, GPR25, GABRB1, CD3E, CCR9, FFAR2, CCR6, CCR5, CCR2, GPR37, ANXA1, RHOG, GPBAR1, TACR3, AGTRAP, PTH2R, AVPR1A, SORCS3, MC3R, PTGER2, PTAFR, CXCR5, CXCR4, CXCR6, GNAI1, GNAI2, FGD4, CXCR1, CXCR2, FLNA, GABRE, GPR157, P2RY13, GABBR1, SORT1, GABRA5, CCL20, P2RY14, GPR6, RAMP1, LGR4, F2RL3, CHRM2, CHRM1, CELSR1, CXCL13, CXCL16, RGS1, CCRL2, PDGFRB, CD97, GHSR, LHCGR, F2R, NPY1R, DGKZ, SPNS1, SUCNR1, CALCRL, GPR87, C5AR1, GPR85, GPR84, ADRB2, GPR82, HRH4, DRD4, HTR1E, CAV1, GPR98, CXCL10, CXCL11, GNB2, TAS2R7, CXCL6, CXCL9, OR1G1, CXCL1, CXCL2, CXCL5, GRM5, PTGIR, GLP2R, XCL1, CX3CR1, LRP1, OR1E1, P2RY6, CCL7, CNR1, P2RY2, OR2W1, CCL5, CCL4, CCL2, S1PR3, OR12D3, S1PR5, TSHR, OR11A1]
GO:0031394;positive regulation of prostaglandin biosynthetic process;10.0;0.9326813400603323;0.8815816818910864;9.59462270081644;954.1434290848206;8.390779266560578;0.03193432189813256;0.8443458537639685;[ANXA1, AVPR1A, PTGS2]
GO:0007187;G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger;6.0;0.6997970393407541;0.6730188322605215;8.578702127993445;26.976932752798508;4.347727998726029;9.028936615729279E-4;0.5454633246350222;[CHRM2, CHRM1, GRM5, RGS1, PTGDR, LHCGR, PTGIR, GPR37, ANXA1, GLP2R, NPY1R, MC3R, ADCY9, CALCRL, PTGER2, FPR1, FPR2, GPR84, ADRB2, GNAI1, GNAI2, CNR1, HRH4, FLNA, CCL2, S1PR3, DRD4, CCR1, ABCA1, GABBR1, HTR1E, TSHR, MARCO, RAMP1, LGR4]
GO:0090026;positive regulation of monocyte chemotaxis;10.0;1.0;0.9152410118609203;9.628524252492122;859.35541097108;6.8867018697843045;0.028761852235543582;0.7674272657460779;[CCR1, CXCL10, CCL5, FPR2, PLA2G7, CCR2]
GO:0090023;positive regulation of neutrophil chemotaxis;11.0;1.0;0.9324289523296623;9.628524252492122;945.710466239641;6.343086423195323;0.03165207822087823;0.7568146869955557;[CXCL6, C5AR1, CXCL1, CXCL2, CXCL5, CXCR2, C3AR1, XCL1]
GO:0002690;positive regulation of leukocyte chemotaxis;9.0;0.7508913569872202;0.7716863036738992;9.33127272902419;423.36221235109986;5.288437257948329;0.014169552246136892;0.6666915524892495;[CXCL6, CXCL9, CXCL1, CXCL13, CXCL2, CXCL5, C3AR1, CCR6, IL6R, CCR2, XCL1, C5AR1, FPR2, PLA2G7, CCL7, CCL5, CXCR2, CCL4, CCR1, TNFSF14, CXCL10, CXCL11]
GO:0043950;positive regulation of cAMP-mediated signaling;8.0;0.8436909121759173;0.7968454560879586;9.517298617381897;239.5163045814748;6.686031174322154;0.008016395163662574;0.7169239451870815;[CXCL10, CXCL9, CXCL11]
GO:0043433;negative regulation of DNA binding transcription factor activity;11.0;0.811012628672052;0.8379352666656883;9.468181602416943;278.0076986152632;4.753193106834193;0.00930466748196786;0.6755074688592472;[PYCARD, HAVCR2, XCL1, SIK1, FLNA, NLRP3, WFS1, NLRP12, CCDC22, EZH2]
GO:0042102;positive regulation of T cell proliferation;9.0;0.7763722522362496;0.7844267512984139;9.424925297250882;564.8543510249671;5.212725436212633;0.018905166792893686;0.6628196464047262;[TFRC, CD3E, PYCARD, IL6R, ICOSLG, CCR2, HLA-DPA1, HAVCR2, ANXA1, PDCD1LG2, XCL1, CD274, BLM, HHLA2, CORO1A, CCL5, LILRB2, CD4, CD6, CD28, HLA-DPB1, CD24]
GO:0042742;defense response to bacterium;6.0;0.7866048967936545;0.7164227609869718;9.193206181234276;69.6526388451159;4.021331414093558;0.0023312111388408135;0.5287713881179241;[, HP, CXCL13, PYCARD, IGHG1, IL6R, SLC11A1, RNASE6, RNASE3, CLEC4D, SLPI, S100A8, SEH1L, C5AR1, KLRK1, NLRP3, IGHA1, ELANE, DEFA4, PRG2, AZU1, DEFA1, LYZ, IGKV3-20, IGHM, CXCL6, HMGB2, CTSG, CD36, CAMP, HAVCR2, ANXA3, TLR1, IGHD, BPI, TLR5, TLR4, LTF, TLR2, CEBPE, HIST1H2BK, NLRC4, IGKC, CCL20, CD4]
GO:0043434;response to peptide hormone;6.0;0.6696747006330769;0.657957662906683;8.712233520617966;71.32532737153224;4.149452513989832;0.0023871945184980284;0.5353235071248601;[CYFIP1, CTGF, EDNRB, AKT1, GHSR, LHCGR, POR, ADCY9, ABCB4, SLC30A10, FOXO1, PRKAR2B, LYN, EGR1, EGR2, TGFB1, CAV1, CDC6, NR4A2, NR4A1, HHEX, ANXA1, ARG1, GLP2R, TGFBR3, CEACAM1, TLR2, RETN, PTGS2, GNAI1, SORT1, TSHR, TEK]
GO:0010629;negative regulation of gene expression;6.0;0.471430776349301;0.558835700764795;6.738152494595957;59.04642522059629;2.349334787147576;0.001976230713800692;0.44326540286011196;[EHMT2, SLA2, AKT1, MEF2C, ATF3, IQGAP3, PKIG, EZH2, MMP12, FLNA, LGR4, GMNN, CTGF, FOXO1, CIITA, LRRK2, FASLG, HHEX, E2F7, KCNQ1, PCBP3, CCR1, EGR1, MSR1, CD28, PTPRK, CD3E, CD36, BANK1, CCNE1, CAV1, HMGA1, MXD1, HMGB2, FBP1, MYB, ELANE, BARD1, NDFIP2, CDKN1A, HAVCR2, PAWR, PAX5, AES, ENG, NR1H2, DACH1, TLE4, MAP2K2, NACC2, WFS1, LSM5, LSM3, BCL6, CNOT3, CR1, RFC1, XCL1, NLRC4, RBBP8, KLF8, KLF5, ZNF608, EDNRB, PPP2R1A, MAGOH, IL1R2, RUNX2, BCL11A, IFNA2, XPO1, MLH1, ARID4A, BASP1, TGFB1, CBX4, NR4A2, MEIS2, RBMX]
GO:0030216;keratinocyte differentiation;6.0;0.8933024483968273;0.7697715367885581;9.377209824211215;25.58801435984686;5.486614186532078;8.564078129062366E-4;0.6037060172430475;[ST14, JAG1, ANXA1, ADAM9]
GO:0071560;cellular response to transforming growth factor beta stimulus;6.0;1.0;0.8231203125901445;9.628524252492122;97.48528473772916;5.788089581116195;0.003262744749111514;0.6191234829421188;[CX3CR1, MEF2C, TGFB1, ARG1, CAV1, NOX4, XCL1]
GO:0050482;arachidonic acid secretion;12.0;1.0;0.9481203125901445;9.628524252492122;224.85573033724626;6.599019797332524;0.007525718937368459;0.7855944919115336;[ACE, ANXA1, DRD4]
GO:0070233;negative regulation of T cell apoptotic process;10.0;0.8259837884571596;0.8282329060895002;9.370695143190021;155.57980234840144;6.7325511899570465;0.005207115971869279;0.7595439928109722;[BLM, SLC46A2, CCL5]
GO:0002725;negative regulation of T cell cytokine production;9.0;0.8933024483968273;0.8428918493787028;9.566003895510788;628.7135452718476;7.697632086000634;0.021042476554793195;0.7898978880348613;[ARG1, IFNA2, XCL1]
GO:0032355;response to estradiol;5.0;0.9326813400603323;0.7565816818910864;9.523163736834295;74.25476231829794;4.940791720728991;0.0024852400698459885;0.542913330229313;[BRCA2, CTGF, PDGFRB, GHSR, ANXA1, DUSP1, TACR3, PCNA, ABCB4, PTGS2, RBBP8, TGFB1, GH1, CD4, EZH2]
GO:0031663;lipopolysaccharide-mediated signaling pathway;6.0;1.0;0.8231203125901445;9.628524252492122;26.50247477320489;6.343086423195323;8.87013979980389E-4;0.647506047256038;[PTAFR, LY96, CCL5, AKT1, CCL2, LYN, TGFB1, CD6, TLR4, TLR2]
GO:2000566;positive regulation of CD8-positive, alpha-beta T cell proliferation;11.0;1.0;0.9324289523296623;9.628524252492122;1381.573672438919;9.083926447120524;0.0462400274809496;0.8969813732811862;[XCL1]
GO:0070234;positive regulation of T cell apoptotic process;10.0;0.8259837884571596;0.8282329060895002;9.370695143190021;155.47524002355703;7.138016298065211;0.00520361636495672;0.7802794972956796;[CD274, CCL5]
GO:0010469;regulation of signaling receptor activity;6.0;0.5916390046238794;0.6189398149020842;7.95454781892045;48.619731222684926;3.470798340732454;0.0016272586491059737;0.5006171011438312;[CXCL13, CTGF, CXCL16, FGF5, VSTM1, TNFSF11, MEF2C, IFNA14, IFNA16, FLT3LG, BTC, IFNA10, TGFA, ADRB2, PDGFC, IFNA21, TGFB1, JAG1, TNFSF14, TNFSF12, INHBA, GH1, CXCL10, CXCL11, PNOC, OGN, CD320, IFNA5, IFNA4, NRP1, CXCL6, IFNA7, CXCL9, IFNA2, CXCL1, FASLG, PRL, IFNA8, CXCL2, CXCL5, XCL1, HBEGF, NLGN1, CLEC12B, RETN, GPNMB, CCL7, CCL5, CCL4, CCL2, EGF, CCL20, CMTM2, FCGR2B]
GO:0001916;positive regulation of T cell mediated cytotoxicity;9.0;0.8653626801206646;0.8289219652406215;9.523163736834295;365.14378084230765;6.518977089658987;0.012221033736724321;0.7296214167088868;[CD1E, CD1B, CD1A, XCL1]
GO:0030850;prostate gland development;5.0;1.0;0.7902410118609202;9.628524252492122;53.04415849917153;7.379178354882098;0.0017753402483239472;0.6676125360964777;[ANXA1]
GO:2000562;negative regulation of CD4-positive, alpha-beta T cell proliferation;11.0;1.0;0.9324289523296623;9.628524252492122;1433.7336516231012;8.390779266560578;0.04798577504331058;0.8615337942327104;[XCL1]
GO:2000563;positive regulation of CD4-positive, alpha-beta T cell proliferation;11.0;1.0;0.9324289523296623;9.628524252492122;1383.791516303458;8.390779266560578;0.04631425671916583;0.8615337942327104;[XCL1]
GO:0008360;regulation of cell shape;6.0;0.6763753087927167;0.6613079669865028;8.690254613899192;41.77565885716001;4.6590798152637145;0.0013981937062970905;0.5613858710120996;[CYFIP1, PLXND1, VRK1, CORO1A, PTK2, ANXA1, RHOG, ARAP3, KIT, RHOU, FGD4, CCL7, PDPN, CCL2]
GO:0045629;negative regulation of T-helper 2 cell differentiation;13.0;1.0;0.9625549647676366;9.628524252492122;2589.4439345822343;8.390779266560578;0.08666635814222527;0.8916598066706847;[ANXA1, BCL6]
GO:0042119;neutrophil activation;6.0;0.8933024483968273;0.7697715367885581;9.4949928598676;20.951462914457938;3.578594911188161;7.012266086544604E-4;0.5061298227699893;[CDA, CYFIP1, ABCA13, C3AR1, RNASE3, RNASE2, PADI2, FPR1, FPR2, ELANE, JUP, AZU1, LYZ, TCN1, SIGLEC9, PYGL, OLR1, ANXA3, ARG1, NFAM1, SERPINB10, PTAFR, ALOX5, GSN, LRG1, SLCO4C1, SIGLEC5, HP, APEH, PYCARD, CLEC5A, LAMP2, CD177, OLFM4, CLEC4D, SLC27A2, S100A8, BRI3, HVCN1, GPR84, ATP8B4, DEFA4, DEFA1, LCN2, ITGAM, FCAR, FCGR3B, CR1, TNFRSF1B, PECAM1, BPI, ACPP, CCL5, FCGR2A, P2RX1, FOLR3, LGALS3, ANPEP, SLC11A1, CHIT1, SLPI, CRISPLD2, STXBP2, MGST1, PRG2, NBEAL2, BST1, VNN1, ORM1, CTSS, GLIPR1, CTSG, CD36, SPTAN1, CAMP, CD33, MME, RHOG, CEACAM1, CEACAM6, TLR2, LILRA3, CXCR1, CXCR2, CD58, LILRB2, LILRB3, QPCT, IL18RAP, CD97, CHRNB4, CD93, OSCAR, DOK3, PRTN3, C5AR1, MGAM, CXCL6, MS4A3, TNFAIP6, CRISP3, CXCL1, SIRPB1, HK3, MMP8, MMP9, CHI3L1, LTF, CLEC12A, RETN, S100P, PTX3]
GO:0035584;calcium-mediated signaling using intracellular calcium source;8.0;1.0;0.875;9.628524252492122;30.117246255164275;6.781341354126479;0.0010079971283984438;0.7217981122146513;[GRM5, CCL20, AZU1]
GO:0045627;positive regulation of T-helper 1 cell differentiation;13.0;1.0;0.9625549647676366;9.628524252492122;2605.164725512912;7.9853141584524145;0.08719251886688177;0.8709243021859774;[ANXA1]
GO:0033280;response to vitamin D;7.0;0.9326813400603323;0.8172600352873667;9.548481544818586;74.55580141320215;6.375876246018314;0.002495315577434836;0.6769819729871445;[TGFB1, ABCB4, PTGS2, CXCL10, CD4, ALPL]
GO:0090630;activation of GTPase activity;7.0;1.0;0.8509193652572005;9.628524252492122;49.337455126924546;5.2552850506314295;0.0016512802222712962;0.6196748871422394;[CXCL13, RHOG, TBC1D9]
GO:0009615;response to virus;5.0;0.7436939687323844;0.6620879962271125;8.801845679307654;27.267803904038782;4.174954806800768;9.126288572378991E-4;0.503748394835965;[CHRM2, PYCARD, STMN1, IFNA14, IFNA16, RNASE6, RNASE2, IFNA10, NLRP3, IFNA21, HMGA1, AZU1, DEFA1, CXCL10, IFNA5, IFNA4, IFNA7, CXCL9, IFNA2, IFNA8, MMP12, TLR8, XCL1, TLR7, UNC93B1, CXCR4, SAMHD1, CCL5, CCL4, LILRB1]
GO:0045744;negative regulation of G-protein coupled receptor protein signaling pathway;7.0;0.6467165523344657;0.6742776414244334;8.623002386890024;189.85671913105512;6.166155715036245;0.006354333529362364;0.6662568552797195;[, ADRB2, GNAI2, CCL5, STMN1]
GO:0032508;DNA duplex unwinding;7.0;0.7980440201809971;0.7499413753476991;9.223059144383958;23.726073882073138;5.734022359845919;7.940903407527885E-4;0.64415753539903;[BLM, MCM7, RAD54B, RUVBL1, ANXA1, HMGA1, RPA1, RAD51, MCM4, MCM6, MCM2]
GO:0071353;cellular response to interleukin-4;6.0;1.0;0.8231203125901445;9.628524252492122;81.6500655361772;6.599019797332524;0.0027327542132076126;0.6605944919115335;[ARG1, CORO1A, XCL1, MCM2]
GO:0071356;cellular response to tumor necrosis factor;6.0;1.0;0.8231203125901445;9.628524252492122;81.6500655361772;4.973052582947213;0.0027327542132076126;0.5774424529526606;[PID1, PYCARD, TCL1A, AKT1, CHI3L1, XCL1, CCL7, CCL5, CCL4, CCL2, CD58, CCL20]
GO:0070301;cellular response to hydrogen peroxide;6.0;1.0;0.8231203125901445;9.628524252492122;361.02555909653125;5.682729065458369;0.012083200561052132;0.6137353412716126;[PCNA, FOXO1, IL18RAP, MYB, ANXA1, ARG1, EZH2]
GO:0014911;positive regulation of smooth muscle cell migration;8.0;0.8933024483968273;0.8216512241984136;9.510741216835738;201.77833622021802;6.280566066213989;0.0067533393245778365;0.6961884407023742;[PDGFRB, DOCK5, NRP1, P2RY6, CCL5, NOX4]
GO:0045070;positive regulation of viral genome replication;8.0;0.8933024483968273;0.8216512241984136;9.474373572664863;85.31211810933421;6.221725566191056;0.0028553198171978322;0.6931793347948383;[CCL5, CD28]
GO:0045071;negative regulation of viral genome replication;8.0;0.8933024483968273;0.8216512241984136;9.474373572664863;85.23964546052278;5.8067817141283475;0.0028528942228632634;0.6719590869034888;[CCL5, SLPI, LTF]
GO:0031532;actin cytoskeleton reorganization;6.0;1.0;0.8231203125901445;9.628524252492122;32.01253927882412;5.788089581116195;0.001071430880247358;0.6191234829421188;[NRP1, FLNA, CXADR, ANXA1, GAB1, KIT]
GO:0032743;positive regulation of interleukin-2 production;6.0;0.8933024483968273;0.7697715367885581;9.427853557029971;65.23665507211369;6.409777797693995;0.002183412136085803;0.6509166472493662;[CD83, CD3E, CCR2, ANXA1, CD4, CD28]
GO:0071636;positive regulation of transforming growth factor beta production;6.0;0.7980440201809971;0.722142322680643;9.34084218004034;65.64212018022187;6.943860283624253;0.0021969826883592772;0.6782296504172152;[MYB, XCL1, PTGS2]
GO:0043615;astrocyte cell migration;6.0;0.8933024483968273;0.7697715367885581;9.377209824211215;22.237500671838706;7.9853141584524145;7.442691350351552E-4;0.7314896500084853;[CCL2, APCDD1]
GO:1900087;positive regulation of G1/S transition of mitotic cell cycle;9.0;0.9326813400603323;0.8625812952104552;9.577230958104572;354.40743100732976;6.409777797693995;0.011861697769835146;0.7240369598395108;[ANXA1, CDC6]
GO:0033031;positive regulation of neutrophil apoptotic process;9.0;1.0;0.896240625180289;9.628524252492122;300.80443177442305;8.390779266560578;0.010067653625077092;0.8253454670833372;[ANXA1]
GO:0007204;positive regulation of cytosolic calcium ion concentration;11.0;0.6835726970475526;0.7742153008534385;9.097896001429952;290.3013502407617;4.174954806800768;0.00971612493830514;0.645936335304707;[CXCL13, SLC8A1, EDNRB, CCRL2, C3AR1, PROK2, PTGDR, F2R, AGTR1, C5AR1, FPR1, FPR3, FPR2, CD19, HRH4, CCR10, CCR1, CAV1, CXCL10, CXCL11, CD24, GPR18, CXCL9, FASLG, CCR9, CCR6, CD36, CCR5, CCR2, CD52, PTGIR, TRPC1, AVPR1A, XCL1, CX3CR1, PTGER2, CXCR5, CXCR4, CXCR6, CXCR1, CXCR2, S1PR3, GPR157, GPR6, P2RX5, CD4, F2RL3]
GO:0006874;cellular calcium ion homeostasis;9.0;0.6324783794010864;0.7124798148808322;8.83001655627435;287.08247441589424;3.7781370657337865;0.009608392061246992;0.5894547304232562;[CXCL13, SLC8A1, EDNRB, CCRL2, C3AR1, PROK2, PTGDR, F2R, ATP1B1, AGTR1, C5AR1, FPR1, FPR3, FPR2, CD19, HRH4, ELANE, CCR10, DRD4, CCR1, TGFB1, WFS1, CAV1, CXCL10, CXCL11, CD24, GPR18, CXCL9, ATP2A3, FASLG, GRM5, CCR9, CCR6, CD36, CCR5, CCR2, TRPC7, CD52, PTGIR, TRPC1, AVPR1A, XCL1, CX3CR1, SLC24A1, SLC24A4, PTGER2, CXCR5, CXCR4, CXCR6, CXCR1, CCL7, SV2A, CCL5, CXCR2, S1PR3, GPR157, TMEM64, GPR6, P2RX5, CD4, GRINA, F2RL3]
GO:0009617;response to bacterium;5.0;0.7508913569872202;0.6656866903545304;8.935377071932177;27.267803904038782;3.9481280100702625;9.126288572378991E-4;0.49214846190264216;[, HP, CXCL13, PYCARD, IGHG1, IL6R, SLC11A1, RNASE6, RNASE3, CHIT1, CLEC4D, SLPI, S100A8, SEH1L, C5AR1, KLRK1, NLRP3, IGHA1, ELANE, DEFA4, CAV1, PRG2, AZU1, DEFA1, LYZ, IGKV3-20, IGHM, CXCL6, HMGB2, CTSG, CD36, CAMP, HAVCR2, ANXA3, TLR1, IGHD, BPI, TLR5, TLR4, LTF, TLR2, CEBPE, HIST1H2BK, PTAFR, NLRC4, IGKC, CCL2, CCL20, CD4, FCGR2B]
GO:0071222;cellular response to lipopolysaccharide;6.0;1.0;0.8231203125901445;9.628524252492122;237.99812851129587;4.786641040901733;0.007965583176863442;0.5679093580234316;[CXCL6, CXCL9, HMGB2, CXCL1, CXCL13, CXCL2, CXCL5, PYCARD, EDNRB, CTSG, CD36, CCR5, HAVCR2, GHSR, MEF2C, ARG1, CD180, PDCD1LG2, TNFRSF1B, ADAM9, TLR4, CX3CR1, CD274, CEBPE, KLRK1, STAP1, NLRP3, CCL2, ABCA1, CCL20, NR1H2, DEFA4, LILRB1, DEFA1, LILRB2, CXCL10, CXCL11]
GO:2000503;positive regulation of natural killer cell chemotaxis;11.0;1.0;0.9324289523296623;9.628524252492122;1000.5321764499969;7.9853141584524145;0.03348691152528284;0.8407982897480031;[CCL7, CCL5, CCL4, XCL1]
GO:0045089;positive regulation of innate immune response;7.0;0.5408746917014966;0.6213567111079488;7.77894521237524;173.7808589209889;4.201124524534153;0.005816288955466338;0.5657650688141469;[ICAM2, PYCARD, IL18RAP, LAG3, CD180, CLEC4D, BTK, S100A8, LY96, KLRK1, LYN, CAV1, SH2D1A, MARCO, ITGAM, HMGB2, CTSS, FFAR2, MUC15, CD36, HAVCR2, MMP12, TLR1, TLR8, TLR10, TLR7, TLR5, TLR4, LTF, TLR2, COLEC12, UNC93B1, NLRC4, CCL5]
GO:0014808;release of sequestered calcium ion into cytosol by sarcoplasmic reticulum;16.0;1.0;1.0;9.628524252492122;562.8564541266966;7.8311634786251565;0.01883829898169905;0.9004860644832351;[CCR5]
GO:0002548;monocyte chemotaxis;7.0;1.0;0.8509193652572005;9.628524252492122;125.46101547564297;6.039404009397101;0.004199067280386423;0.6597747671587765;[ANXA1, CCL20, TNFRSF11A, LGALS3, CCL7, CCL5, CCL4, TNFSF11, CCL2, XCL1, IL6R, CCR2]
GO:0071223;cellular response to lipoteichoic acid;6.0;1.0;0.8231203125901445;9.628524252492122;155.87545856417063;7.474488534686424;0.005217011319337755;0.7053660038532718;[CCL20, TREM2, CD36, TLR2]
GO:0070098;chemokine-mediated signaling pathway;7.0;0.7307253602413294;0.7162820453778652;8.999915593069748;30.19135422731818;5.459585514144159;0.00101047745553359;0.6301228223472235;[CX3CR1, CXCL6, CXCL9, CXCR5, CXCR4, CXCL1, CXCR6, CXCL13, CXCL2, CXCL5, CXCR1, CCL7, CCL5, CXCR2, CCRL2, CCL4, CCR9, CCL2, CCR6, CCR5, CCR10, CCR2, CCR1, CCL20, CXCL10, CXCL11, XCL1]
GO:0043066;negative regulation of apoptotic process;7.0;0.5640623033008358;0.6329505169076184;7.792313020693233;81.07407142393629;2.9735683700721314;0.0027134762086319553;0.5029877899877601;[AKT1, PROK2, MEF2C, CLDN7, SLC30A10, FIGNL1, SFN, BARD1, PLK2, AZU1, CDKN1A, CHL1, ANXA1, DUSP1, ANXA5, PTGS2, UNG, FLNA, GABRA5, CLEC5A, F2R, MSH2, BLM, CORO1A, FOXO1, WFS1, TNFRSF10C, TNFRSF10B, DHCR24, BCL6, LRRK2, FASLG, TNFRSF1B, ADAMTS20, CX3CR1, LRP1, NLRC4, CCL5, CCL2, TIE1, IL2RB, SLC46A2, LGALS3, TCL1A, EDNRB, FLT3LG, BTC, POR, EPHA3, EGR3, BCL11B, TNFSF14, PTK2, VNN1, CD28, NRP1, CCR5, CEACAM6, KIT, GNAI2, CXCR2, PDPN, LILRB1, GRINA, PDGFRB, GHSR, C5AR1, PSEN2, CBX4, CAV1, NR4A2, HMGB2, SLC40A1, NUP62, MMP9, LTF, DLL1, TEK]
GO:0045087;innate immune response;4.0;0.6799073451904818;0.5899536725952409;8.162187183698695;26.470038109745843;3.422703586883119;8.859283540455166E-4;0.42503722060519694;[, SLA2, LGALS3, RNASE6, RNASE3, SLPI, BTK, LY9, KLRK1, SLAMF7, IGHA1, LYN, KIR2DS1, KIR2DS2, SH2D1A, KIR2DS4, KIR2DS5, PTK2, MARCO, VNN1, IFNA5, IFNA4, IGHM, IFNA7, IFNA2, IFNA8, CAMP, HAVCR2, ANXA1, ARG1, TLR1, IGHD, TLR8, TLR10, TLR7, TLR5, TLR4, TLR2, LILRA5, IGKC, KIR3DL1, LGR4, PYCARD, IGHG1, GRAP2, CLEC5A, CD177, IFNA14, IFNA16, CD180, CLEC4D, S100A8, IFNA10, BLK, LY96, CORO1A, NLRP3, IFNA21, TGFB1, DEFA4, DEFA1, BMX, LCN2, ITGAM, CRISP3, HMGB2, TREM2, TREM1, SIRPB1, CR2, CR1, LTF, COLEC12, UNC93B1, HIST1H2BK, NLRC4, CD6, PTX3]
GO:0070374;positive regulation of ERK1 and ERK2 cascade;11.0;0.9326813400603323;0.8987696223598284;9.604993755081928;1178.864923326294;4.330336256014159;0.03945554807418015;0.6538825498434562;[CTGF, PYCARD, TNFSF11, PDGFRB, F2R, EPHA3, C5AR1, FPR2, TNFRSF11A, SLC30A10, PDGFC, CCR1, TGFB1, MARCO, NOX4, NRP1, TREM2, CD36, HAVCR2, KIT, CHI3L1, XCL1, GNAI2, GPNMB, CCL7, CCL5, CCL4, CCL2, CCL20, TIE1, CD4, TEK]
GO:0006909;phagocytosis;6.0;0.9326813400603323;0.7894609826203107;9.4949928598676;28.437470009997963;5.618190544320798;9.517765291732001E-4;0.610434838299289;[NCF4, CD36, ANXA1, CD93, ANXA3, SLC11A1, DNM2, PECAM1, PRTN3, CD302, LRP1, CEBPE, PLD4, CORO1A, ELANE, MARCO]
GO:0071347;cellular response to interleukin-1;6.0;1.0;0.8231203125901445;9.628524252492122;81.6500655361772;5.446340287394138;0.0027327542132076126;0.6016464081682054;[PYCARD, CCL7, CCL5, CCL4, CCL2, CCL20, KMO, CHI3L1, XCL1, RBMX]
GO:0072679;thymocyte migration;8.0;0.8933024483968273;0.8216512241984136;9.533214072687796;31.84507234699532;9.083926447120524;0.0010658259127495017;0.839552420951524;[CCL20, CCR6]
GO:0002826;negative regulation of T-helper 1 type immune response;8.0;0.8933024483968273;0.8216512241984136;9.503361109538115;172.20109340032639;7.8311634786251565;0.005763415625186428;0.7754860644832351;[XCL1, HAVCR2]
GO:0071621;granulocyte chemotaxis;8.0;0.8653626801206646;0.8076813400603323;9.434368238051164;96.32399332974941;5.311165509025885;0.0032238773707808457;0.6466132511260384;[CXCL6, CXCL9, CSF3R, C5AR1, CXCL1, CXCL13, CXCL2, CXCL5, LGALS3, CXCR1, CCL7, CCL5, CXCR2, CCL4, CCL2, CXADR, ANXA1, CCL20, CXCL10, CXCL11, XCL1, S100A8]
GO:0071346;cellular response to interferon-gamma;6.0;1.0;0.8231203125901445;9.628524252492122;81.6500655361772;5.266214121163619;0.0027327542132076126;0.5924347476504533;[HLA-DPA1, KIF16B, XCL1, TLR4, TLR2, STXBP2, CCL7, CCL5, CCL4, CCL2, CD58, GSN, CCL20, ZYX]
GO:2000502;negative regulation of natural killer cell chemotaxis;11.0;1.0;0.9324289523296623;9.628524252492122;1002.759017369874;9.083926447120524;0.03356144188684441;0.8969813732811862;[KLRK1, CCL2]
GO:0032733;positive regulation of interleukin-10 production;6.0;0.8933024483968273;0.7697715367885581;9.427853557029971;65.23665507211369;6.375876246018314;0.002183412136085803;0.6491829203200885;[CD274, CD83, PYCARD, CD28, XCL1, TLR4, TLR2]
